


WE CLAIM:

1. A compound having the general formula (II):



wherein

- Q is alkyl, alkenyl or alkynyl optionally substituted with halogen, carboxyl, alkyl or aryl, and wherein one or more carbon atoms are optionally replaced with O, N, NR<sub>6</sub>, S, SO, or SO<sub>2</sub>;
- R<sub>1</sub> is hydrogen or is selected from the group consisting of alkyl, alkenyl and alkynyl, each of which is optionally substituted with hydroxyl, halogen, amino, nitro, carboxyl, a carbocycle, or a heterocycle; or R<sub>1</sub> is a carbocycle or heterocycle optionally substituted with hydroxyl, oxo, halogen, amino, or nitro;
- R<sub>3</sub> and R<sub>4</sub> are independently selected from the group consisting of H, hydroxyl, halogen, amino, nitro, carboxyl, alkyl, alkenyl, alkynyl, a carbocycle and a heterocycle, wherein said alkyl, alkenyl, alkynyl, carbocycle and heterocycle groups are optionally substituted with one or more substituents selected from the group consisting of hydroxyl, halogen, amino, oxo and carboxyl, and optionally one or more carbon atoms of said alkyl,

alkenyl and alkynyl group is replaced with N, NR<sub>6</sub>, O, S, SO or SO<sub>2</sub>;

R<sub>6</sub> is hydrogen, alkyl, alkenyl or alkynyl;

R<sub>7</sub> is hydrogen, hydroxyl, halogen, alkyl, alkoxy or halogen substituted alkyl;

R<sub>8</sub> is H, alkyl, alkenyl or alkynyl;

R<sub>9</sub> is H or NR<sub>11</sub>R<sub>11'</sub>, wherein R<sub>11</sub> and R<sub>11'</sub> are independently H, acyl or and amino acid residue; or one of R<sub>11</sub> and R<sub>11'</sub> together with R<sub>8</sub> form a heterocycle;

R<sub>10</sub> is O or S;


m and n are independently 1, 2 or 3;







p is an integer from 1 to 5;

and salts, solvates and hydrates thereof.







2. The compound according to claim 1, wherein Q is an alkyl chain of 1 to 3 carbon atoms in length.
3. The compound according to claim 2, wherein said alkyl chain is 2 carbon atoms in length.
4. The compound according to claim 2, wherein one of the carbon atoms in said alkyl chain is replaced with an oxygen atom.
5. The compound according to claim 4, wherein said oxygen atom is adjacent to the ring.
6. The compound according to claim 1, wherein R<sub>1</sub> is H.
7. The compound according to claim 1, wherein R<sub>3</sub> and R<sub>4</sub> are both H.
8. The compound according to claim 1, wherein R<sub>6</sub> is H.

9. The compound according to claim 1, wherein p is the integer 1, and R<sub>7</sub> is OH at the para-position.
10. The compound according to claim 1, wherein R<sub>8</sub> is H and R<sub>9</sub> is H or NR<sub>11</sub>R<sub>11'</sub>, wherein R<sub>11</sub> is H and R<sub>11'</sub> is H or C<sub>1-4</sub> alkanoyl.
11. The compound according to claim 1, wherein R<sub>9</sub> is NR<sub>11</sub>R<sub>11'</sub>, wherein R<sub>11</sub> together with R<sub>8</sub> form a 5-member heterocycle.
12. The compound according to claim 11, wherein R<sub>11'</sub> is H or C<sub>1-4</sub> alkanoyl.
13. A compound according to claim 1 selected from the group consisting of




















5




10



5





5

and salts, solvates and hydrates thereof.

14. A method of treating a disease or condition mediated by  $\alpha_4$  integrin receptors or ligands of  $\alpha_4$  integrin receptors in a mammal comprising administering to said mammal an effective amount of a compound of according to claim 1.

15. A method according to claim 14, wherein said disease or condition is selected from the group consisting of rheumatoid arthritis, asthma, psoriasis, multiple sclerosis, inflammatory bowel disease including ulcerative colitis, pouchitis and  
5 Crohn's disease, Celiac disease, nontropical Sprue, graft-versus-host disease, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, pericholangitis, chronic sinusitis, chronic bronchitis, pneumonitis, collagen disease, eczema, and systemic lupus erythematosus.

16. A method of inhibiting binding of an  $\alpha_4$  integrin to a protein ligand comprising contacting said  $\alpha_4$  integrin with a compound of claim 1.